Overview

Peripheral neuropathy is one of the most common side effects of oxaliplatin (OXA)-based chemotherapy for patients treated for digestive cancers, disabling and dose-limiting. Several strategies have been studied for the treatment of oxaliplatin-related sensory neuropathy. Several pharmacological and non-pharmacological therapeutic strategies have been explored to relieve peripheral neuropathic pain. Non-pharmacological interventions have been shown to be potentially beneficial for patients suffering from chemotherapy-induced neurotoxicity. The objective of this prospective study is to evaluate the effectiveness of photobiomodulation on the reduction of neuropathic pain in patients who developed painful, cumulative peripheral neuropathy that appeared under the effect of the treatment.

Eligibility

Inclusion Criteria:

• Recent diagnosis of digestive cancer
• 12 planned cycles of oxaliplatin
• Ability to understand and willingness to sign an informed consent form before starting any study procedures
• Patient benefiting from French health insurance

Exclusion Criteria:

• History of neuropathy before the start of the study,
• Symptomatic treatment of pain (or neuropathic pain),
• Patient with a psychotic disorder,
• Patient with diabetic neuropathy,
• Patient with metastatic cancer
• Patient with renal insufficiency,
• Adults under guardianship or curatorship,
• Vulnerable people